Should I Buy ACAD Stock in 2026?

Data-driven analysis and honest assessment for ACADIA Pharmaceuticals Inc

Analysis Updated:
CAUTIONSeveral concerns warrant careful consideration

Current Price: $0.00P/E: 15.3

Decision Score

5.4/10

Hold

Based on 6 fundamental factors

Score Breakdown:

Valuation (20%)7/10

Reasonable P/E of 15.3

Growth (20%)5/10

Growth data limited

Profitability (20%)5/10

Profitability data limited

Financial Health (15%)5/10

Financial health data limited

Cash Flow (15%)5/10

Cash flow data limited

Insider Activity (10%)5/10

No recent insider activity

Key Investment Metrics

Current Price

$0.00

P/E Ratio

15.29

Revenue Growth

N/A

Profit Margin

N/A

Market Cap

$3.5B

Dividend Yield

None

How ACAD Compares to Competitors

Understanding how ACAD stacks up against peers helps inform your investment decision.

How ACAD Compares to Peers

Upcoming Events for ACAD

+5 Reasons TO Buy ACAD

Limited data available to identify compelling buy reasons. Consider this a yellow flag.

-5 Reasons NOT to Buy ACAD

1. Minimal revenue growth

low risk

Growth of 0.0% barely keeps pace with inflation.

Who Should Buy ACAD?

Investment Profile

Risk Level

High

Recommended Holding Period

3-5 years

Best For:

    Not Suitable For:

    • Growth Investors

      Limited 0% growth may disappoint

    • Income-Focused Retirees

      No dividend paid

    • Risk-Averse Investors

      High risk may cause uncomfortable volatility

    • Large Position Traders

      Lower liquidity may impact execution

    Consider These Alternatives

    If you're interested in ACAD, compare these Healthcare peers:

    Pro tip: Compare ACAD directly with competitors using our comparison tool to see which stock better fits your criteria.

    Get the Full Picture

    Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for ACAD

    Frequently Asked Questions

    What is ACAD stock price today?

    Visit our real-time dashboard for the current ACAD stock price and live market data.

    Is ACAD stock going up or down today?

    ACAD stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

    Should I buy ACAD stock now?

    The decision to buy ACAD depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

    Is ACAD a buy, hold, or sell right now?

    Our AI-powered analysis provides buy/hold/sell recommendations for ACAD based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

    Is ACAD stock overvalued or undervalued?

    ACAD currently trades at a P/E ratio of 15.29 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if ACAD is fairly priced.

    What is ACAD's P/E ratio?

    ACAD has a price-to-earnings (P/E) ratio of 15.29, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

    What is ACAD's market cap?

    ACAD (ACADIA Pharmaceuticals Inc) has a market capitalization of $3.51 billion, making it a small-cap stock.

    What is ACAD's price to book ratio?

    Price-to-book ratio for ACAD is available on our dashboard along with other valuation metrics.

    Similar Investment Decisions

    Explore investment analyses for stocks similar to ACADIA Pharmaceuticals Inc

    Explore Categories

    Disclaimer

    This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.